One of the goals of precision medicine is to uncover selective vulnerabilities in various cancers. A notable success has been the development of PARP inhibitors for the treatment of breast and ovarian cancers with mutations in BRCA genes. Only two years ago, it was discovered that cancers with microsatellite instability (MSI) were selectively dependent on the RecQ DNA helicase WRN. Subsequently, the molecular mechanism underlying WRN dependency in MSI cancers was uncovered. Here, we review how these developments have led to a promising new drug target in MSI cancers.

中文翻译：

---

WRN解旋酶：解决微卫星不稳定癌症的新目标

精准医学的目标之一是发现各种癌症的选择性脆弱性。一个显着的成功是开发了用于治疗具有 BRCA 基因突变的乳腺癌和卵巢癌的 PARP 抑制剂。仅在两年前，人们发现具有微卫星不稳定性 (MSI) 的癌症选择性地依赖于 RecQ DNA 解旋酶 WRN。随后，揭示了 MSI 癌症中 WRN 依赖性的分子机制。在这里，我们回顾了这些发展如何导致 MSI 癌症的有前途的新药物靶点。